18 results on '"Mizumoto C"'
Search Results
2. For whom does determinism undermine moral responsibility? Surveying the conditions for free will across cultures
- Author
-
Hannikainen, aEmail Author, I. R., Machery, E. b., Rose, D. c., Stich, S. d., Olivola, C. Y. e., Sousa, P. f., Cova, F. g., Buchtel, E. E. h., Alai, M. i., Angelucci, A. i., Berniûnas, R. j., Chatterjee, A. k., Cheon, H. l., Cho, I. -R. l., Cohnitz, D. m., Dranseika, V. n., Eraña, Lagos, Ghadakpour, Á. o., Grinberg, L. p., Hashimoto, M. q., Horowitz, T. r., Hristova, A. s., Jraissati, E. q., Kadreva, Y. t., Karasawa, V. q., Kim, K. r., Kim, H. u., Lee, Y. v., Mauro, M. u., Mizumoto, C. w., Moruzzi, M. x., Ornelas, S. y., Osimani, J. z., Aa, B., Romero, C. o., Rosas, López, Ab, A., Sangoi, M. i., Sereni, Ac, A., Songhorian, Ad, S., Struchiner, N. a., Tripodi, Vera, Ae, V., Usui, Af, N., Vázquez del Mercado, Vosgerichian, A. o., Zhang, H. A. s., Ag, X., Zhu, and Ah, J.
- Subjects
sourcehood ,PsyArXiv|Social and Behavioral Sciences|Social and Personality Psychology|Individual Differences ,PsyArXiv|Social and Behavioral Sciences|Social and Personality Psychology|Moral Behavior ,compatibilism ,situationism ,PsyArXiv|Social and Behavioral Sciences|Social and Personality Psychology|Personality and Situations ,PsyArXiv|Social and Behavioral Sciences|Cognitive Psychology|Reasoning ,PsyArXiv|Social and Behavioral Sciences|Cognitive Psychology|Judgment and Decision Making ,PsyArXiv|Social and Behavioral Sciences|Social and Personality Psychology ,free will, compatibilism, cognitive style, situationism, dispositionism, sourcehood, alternate possibilities ,alternate possibilities ,bepress|Social and Behavioral Sciences|Psychology ,PsyArXiv|Social and Behavioral Sciences|Cultural Psychology|Cross-cultural Psychology ,PsyArXiv|Social and Behavioral Sciences|Cultural Psychology ,bepress|Social and Behavioral Sciences|Psychology|Cognitive Psychology ,PsyArXiv|Social and Behavioral Sciences|Theory and Philosophy of Science ,cognitive style ,PsyArXiv|Social and Behavioral Sciences ,PsyArXiv|Social and Behavioral Sciences|Social and Personality Psychology|Cultural Differences ,bepress|Social and Behavioral Sciences ,PsyArXiv|Social and Behavioral Sciences|Cognitive Psychology ,bepress|Social and Behavioral Sciences|Psychology|Social Psychology ,bepress|Social and Behavioral Sciences|Psychology|Personality and Social Contexts ,bepress|Social and Behavioral Sciences|Psychology|Theory and Philosophy ,free will ,dispositionism - Abstract
Philosophers have long debated whether, if determinism is true, we should hold people morally responsible for their actions since in a deterministic universe, people are arguably not the ultimate source of their actions nor could they have done otherwise if initial conditions and the laws of nature are held fixed. To reveal how non-philosophers ordinarily reason about the conditions for free will, we conducted a cross-cultural and cross-linguistic survey (N = 5,268) spanning twenty countries and sixteen languages. Overall, participants tended to ascribe moral responsibility whether the perpetrator lacked sourcehood or alternate possibilities. However, for American, European, and Middle Eastern participants, being the ultimate source of one’s actions promoted perceptions of free will and control as well as ascriptions of blame and punishment. By contrast, being the source of one’s actions was not particularly salient to Asian participants. Finally, across cultures, participants exhibiting greater cognitive reflection were more likely to view free will as incompatible with causal determinism. We discuss these findings in light of documented cultural differences in the tendency toward dispositional versus situational attributions.
- Published
- 2019
3. Monoclonal antibodies with a high degree of specificity for Listeria monocytogenes serotype 4b
- Author
-
Kathariou, S., Mizumoto, C., Allen, R. D., Fok, A.K., and Benedict, A.A.
- Subjects
Monoclonal antibodies -- Research ,Listeria monocytogenes -- Research ,Biological sciences - Abstract
Three monoclonal antibodies (MAbs) c74.33, c74.180 and c74.22, exhibit high degrees of specificity for Listeria monocytogenes serotype 4b. Antibody c74.22 fails to recognizes few epidemic-associated strains, while other two recognize all the serotype 4b strains. Heat treatment nullifies the activity of c74.22 but not of the c74.33 MAb. c74.22 recognizes a surface antigen that has the capacity of bacteria to enter cultured mammalian cells.
- Published
- 1994
4. Serum hepcidin level and erythropoietic activity after hematopoietic stem cell transplantation
- Author
-
Kanda, J., primary, Mizumoto, C., additional, Kawabata, H., additional, Tsuchida, H., additional, Tomosugi, N., additional, Matsuo, K., additional, and Uchiyama, T., additional
- Published
- 2008
- Full Text
- View/download PDF
5. Group A Streptococcal Isolates Temporally Associated with Acute Rheumatic Fever in Hawaii: Differences from the Continental United States
- Author
-
Erdem, G., primary, Mizumoto, C., additional, Esaki, D., additional, Reddy, V., additional, Kurahara, D., additional, Yamaga, K., additional, Abe, L., additional, Johnson, D., additional, Yamamoto, K., additional, and Kaplan, E. L., additional
- Published
- 2007
- Full Text
- View/download PDF
6. Successful treatment of lung cancer coexisting with B‑cell lymphoma with pembrolizumab following rituximab‑included chemotherapy: A case report.
- Author
-
Natori D, Ozasa H, Shima Y, Mizumoto C, Suminaga K, Nomizo T, Ajimizu H, Yoshida H, and Hirai T
- Abstract
The combined occurrence of lung cancer and B-cell lymphoma, such as mucosa-associated lymphoid tissue (MALT) lymphoma, is rare. The efficacy and safety of immune checkpoint inhibitors (ICIs) remain unknown in this population of patients, and the occurrence of ICI-induced exacerbation of lymphoma is concerning. The present study describes a case of successful treatment with pembrolizumab following rituximab-containing chemotherapy for lung cancer complicated by MALT lymphoma. The patient was a 69-year-old woman diagnosed with MALT lymphoma based on a biopsy of stomach ulcerative lesions, and advanced lung cancer based on a biopsy of a lymph node in the left pulmonary hilum. Complete remission was achieved after one cycle of rituximab and bendamustine therapy for MALT lymphoma. Pembrolizumab monotherapy was subsequently initiated, resulting in a good response for lung cancer without recurrence or exacerbation of the lymphoma. In conclusion, the present study suggested that pembrolizumab, following rituximab-containing therapy, could be a treatment option for patients with lung cancer coexisting with MALT lymphoma., Competing Interests: The authors declare that they have no competing interests., (Copyright: © 2024 Natori et al.)
- Published
- 2024
- Full Text
- View/download PDF
7. Methotrexate‑related other iatrogenic immunodeficiency‑associated lymphoproliferative disorder in the CNS and medication‑related osteonecrosis of the jaw occurring simultaneously: A case report.
- Author
-
Kato T, Mizumoto C, Inoue F, Watanabe T, Yamanaka S, Fukuhara S, and Nakao K
- Abstract
Methotrexate-related other iatrogenic immunodeficiency-associated lymphoproliferative disorder (MTX-OIIA-LPD) is prone to extranodal involvement but rarely involves the central nervous system (CNS). The present study reports a case of MTX-OIIA-LPD of the CNS discovered during medication-related osteonecrosis of the jaw (MRONJ) treatment in a 76-year-old woman with rheumatoid arthritis (RA). The chief complaint of the patient was bone exposure and pain in the right mandibular molar. The patient had been receiving MTX for RA and alendronate sodium hydrate for osteoporosis, followed by denosumab. Treatment was initiated based on a diagnosis of MRONJ. However, the patient experienced lightheadedness and floating dizziness afterwards. Examinations revealed scattered neoplastic lesions in the brain. The histopathological diagnosis was diffuse large B-cell lymphoma. A systemic search also revealed adrenal involvement. Since the patient was taking MTX, a diagnosis of MTX-OIIA-LPD was made and MTX was discontinued. Chemotherapeutic agents were administered since the central lesions became symptomatic. The MTX-OIIA-LPD lesions in the brain and adrenal glands completely resolved 8 months after onset. The physical condition of the patient improved, and the bone-exposed areas became epithelialized. Reports on MTX-LPD in the oral and maxillofacial region are few, which may delay its diagnosis. Therefore, biopsy of oral lesions in patients with MRONJ who are taking MTX and collaboration with related diagnostic departments, such as rheumatology and hematology, must be done to initiate the diagnosis and treatment of extraoral MTX-LPD., Competing Interests: The authors declare that they have no competing interests., (Copyright: © Kato et al.)
- Published
- 2023
- Full Text
- View/download PDF
8. Impact of Antimicrobial Drug-Drug Interactions on Acute Kidney Injury after Allogeneic Hematopoietic Cell Transplantation.
- Author
-
Wada F, Arai Y, Jo T, Mizumoto C, Kanda J, Kitawaki T, Nishikori M, Yamashita K, and Takaori-Kondo A
- Abstract
Acute kidney injury (AKI) is one of the major complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The use of multiple antimicrobials is one of the major causes of post-transplantation AKI, owing to the potential nephrotoxicity of each agent and of drug-drug interactions (DDIs). No satisfactory reports on DDIs the field of allo-HSCT have been published. We performed a retrospective analysis to compare the incidence of AKI within 100 days post-transplantation. A total of 465 allo-HSCTs in 416 patients were analyzed, and the cumulative incidence of AKI was 40.0%. AKI was associated with significantly reduced overall survival (hazard ratio [HR], 2.66; 95% confidence interval [CI] 1.95 to 3.55; P < .01) and increased transplantation-related mortality (HR, 4.77, 95% CI, 2.90 to 7.88; P < .01). A higher incidence of AKI was significantly associated with the use of ciprofloxacin, cefepime, tazobactam/piperacillin, meropenem, vancomycin, liposomal amphotericin B, ganciclovir, and foscarnet. Among these drugs, combinations of vancomycin plus tazobactam/piperacillin (HR, 2.23; P = .09 for interaction), ganciclovir plus cefepime (HR, 5.93; P = .04), and ganciclovir plus meropenem (HR, 2.63; P = .12) synergistically increased the risk of AKI, whereas combinations involving teicoplanin did not. This is the first report dealing with DDIs after allo-HSCT, indicating that such combinations should be avoided to preserve renal function and reduce AKI-related morbidity and mortality., (Copyright © 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
9. Risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy.
- Author
-
Jo T, Arai Y, Kitawaki T, Nishikori M, Mizumoto C, Kanda J, Yamashita K, Nagao M, and Takaori-Kondo A
- Subjects
- Humans, Calcium, Leukapheresis, Cell- and Tissue-Based Therapy, Body Weight, Risk Assessment, Hypercalcemia therapy, Hypocalcemia etiology, Hypocalcemia therapy
- Abstract
Optimized management of citrate-induced hypocalcemia is required to provide safe leukapheresis. We prospectively analyzed subjects who underwent leukapheresis for cytotherapy, and evaluated serum ionized (iCa) concentrations before, at the end of, and 1 h after leukapheresis. During leukapheresis, calcium gluconate solution was continuously supplemented intravenously with hourly measurement of iCa. 76 patients including 49 lymphapheresis for chimeric antigen receptor T-cell therapy and 27 stem cell collections were enrolled. Median processing blood volume was 10 L (range, 6-15 L). Fluctuating hypercalcemia, in which the iCa concentration rose above its upper limit 1 h after leukapheresis, was observed in 58 subjects (76.3%). Multivariate analysis revealed that higher ratios of processing blood volume to body weight, more rapid calcium supplementation, and lower iCa concentration at the end of leukapheresis significantly increased elevation of serum iCa concentration by 1 h after leukapheresis. Based on multivariate analyses, we developed a formula and a diagram that accurately estimates serum iCa concentration 1 h post-leukapheresis. This suggests optimal targets for iCa concentration and calcium supplementation rates. In cases with high ratios of processing blood volume to body weight, slowing the rate of blood processing, rather than increasing calcium supplementation should safely alleviate hypocalcemia during leukapheresis without inducing hypercalcemia thereafter., (© 2023. Springer Nature Limited.)
- Published
- 2023
- Full Text
- View/download PDF
10. Significance of Omitting Day 11 Mini-Dose Methotrexate for GVHD Prophylaxis After Unrelated Bone Marrow Transplantation.
- Author
-
Nakamura N, Wada F, Kondo T, Aoki K, Arai Y, Mizumoto C, Kanda J, Kitawaki T, Yamashita K, and Takaori-Kondo A
- Subjects
- Humans, Bone Marrow Transplantation adverse effects, Retrospective Studies, Transplantation, Homologous adverse effects, Methotrexate therapeutic use, Graft vs Host Disease etiology, Graft vs Host Disease prevention & control
- Abstract
The combination of calcineurin inhibitors and short-term methotrexate has been used as a standard graft-versus-host-disease (GVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation. Mini-dose methotrexate (mini-MTX), consisting of 5 mg/m
2 /d on days 1, 3, 6, and 11, is occasionally selected as an alternative considering toxicity. The significance of day 11 administration remains unclear. We performed a retrospective study of 135 cases of unrelated bone marrow transplantation at our institute between 2006 and 2019 and compared the outcomes between day 11 MTX dose omitted (n = 72) and full-doses of mini-MTX (n = 63). In total cohort, the 4-year overall survival (OS) was 58.7 %, and the omitted group showed poor GVHD/relapse-free-survival (P = .01) with comparable OS (P = .11) and relapse-free survival (P = .11). Human leukocyte antigen (HLA) mismatch is a major risk factor for severe GVHD. We analyzed the impact of omitting day 11 MTX in 2 cohorts from HLA matched or mismatched donors. In both cohorts, the omitted group had a higher risk of severe acute and chronic GVHD. In conclusion, the omission of day 11 MTX was associated with a higher risk of severe GVHD. Therefore the omission of the day 11 dose is not recommended., (Copyright © 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
11. T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy.
- Author
-
Wada F, Jo T, Arai Y, Kitawaki T, Mizumoto C, Kanda J, Nishikori M, Yamashita K, Nagao M, and Takaori-Kondo A
- Subjects
- Humans, Leukapheresis, T-Lymphocytes, Neoplasm Recurrence, Local drug therapy, Receptors, Antigen, T-Cell, Cell- and Tissue-Based Therapy, Cell Count, Antigens, CD19, Receptors, Chimeric Antigen, Lymphoma, Large B-Cell, Diffuse pathology
- Abstract
Prediction of responses to chimeric antigen receptor (CAR)-T cell therapies is essential to maximize their therapeutic efficacy for diffuse large B-cell lymphoma (DLBCL). While several tumor-intrinsic risk factors of resistance and/or early relapse have been identified, clinically useful markers that determine potential activity of CAR-T cells have not been fully investigated. T-cell property at the time of leukapheresis may serve as such a marker. Therefore, we evaluated the clinical impact of CD3
+ cell count in peripheral blood at leukapheresis on clinical outcomes of CAR-T cell therapy. In total, 44 patients with relapsed or refractory (r/r) DLBCL who received tisagenlecleucel at Kyoto University Hospital were included. According to CD3+ cell counts, patients were categorized into CD3LOW and CD3HIGH groups with a threshold of 553/μL, based on receiver operating characteristic curve analysis. 1-year progression-free survival was significantly higher in the CD3HIGH group than the CD3LOW group (68.3% vs. 17.3%; adjusted hazard ratio [aHR], 0.37; p = 0.042). Overall survival was also superior in the CD3HIGH group (aHR, 0.24; p = 0.043). Moreover, higher CD3+ cell counts at leukapheresis were associated with significantly higher lymphocyte counts in peripheral blood at day 7 after CAR-T cell infusion (median 860 vs. 420/μL, P = 0.021), suggesting more extensive expansion of infused CAR-T cells in vivo. In conclusion, we demonstrated that the CD3+ cell count at leukapheresis predicts both expansion of CAR-T cells after infusion and outcomes of CAR-T cell therapy, and are useful for building comprehensive therapeutic strategies at the time of leukapheresis., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
12. Relative hypercoagulation induced by suppressed fibrinolysis after tisagenlecleucel infusion in malignant lymphoma.
- Author
-
Yamasaki-Morita M, Arai Y, Ishihara T, Onishi T, Shimo H, Nakanishi K, Nishiyama Y, Jo T, Hiramatsu H, Mitsuyoshi T, Mizumoto C, Kanda J, Nishikori M, Kitawaki T, Nogami K, Takaori-Kondo A, Nagao M, and Adachi S
- Subjects
- Adult, Antigens, CD19, Fibrinolysis, Humans, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, Non-Hodgkin drug therapy, Plasminogen Activator Inhibitor 1, Prospective Studies, Receptors, Antigen, T-Cell therapeutic use, Blood Coagulation Disorders drug therapy, Blood Coagulation Disorders etiology, Receptors, Chimeric Antigen therapeutic use, Thrombophilia
- Abstract
Anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy has facilitated progress in treatment of refractory/relapsed diffuse large B-cell lymphoma (DLBCL). A well-known adverse event after CAR-T therapy is cytokine release syndrome(CRS). However, the etiology and pathophysiology of CRS-related coagulopathy remain unknown. Therefore, we conducted a prospective cohort study to comprehensively analyze coagulation/ fibrinolysis parameters present in peripheral blood of adult DLBCL patients treated with tisagenlecleucel in a single institution. Samples were collected from 25 patients at 3 time points: before lymphocyte-depletion chemotherapy and on days 3 and 13 after CAR-T infusion. After infusion, all patients except 1 experienced CRS, and 13 required the administration of tocilizumab. A significant elevation in the plasma level of total plasminogen activator inhibitor 1 (PAI-1), which promotes the initial step of coagulopathy (mean, 22.5 ng/mL before lymphocyte-depletion and 41.0 on day 3, P = .02), was observed at the onset of CRS. Moreover, this suppressed fibrinolysis-induced relatively hypercoagulable state was gradually resolved after CRS remission with normalization of total PAI-1 to preinfusion levels without any organ damage (mean values of soluble fibrin: 3.16 µg/mL at baseline, 8.04 on day 3, and 9.16 on day 13, P < .01; and mean PAI-1: 25.1 ng/mL on day 13). In conclusion, a hypofibrinolytic and relatively hypercoagulable state concomitant with significant total PAI-1 elevation was observed at the onset of CRS even in DLBCL patients with mild CRS. Our results will facilitate understanding of CRS-related coagulopathy, and they emphasize the importance of monitoring sequential coagulation/fibrinolysis parameters during CAR-T therapy., (© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
13. Concurrent Autoimmune Neutropenia and Idiopathic Thrombocytopenic Purpura Associated with IgG4-related Diease.
- Author
-
Shimazu Y, Uchiyama T, Mizumoto C, Takeoka T, Tsuji M, Tomo K, Takaori K, Sakai N, Okuno T, and Ohno T
- Subjects
- Autoimmune Diseases immunology, Humans, Inflammation complications, Lung Diseases, Interstitial complications, Male, Middle Aged, Nephritis, Interstitial complications, Autoimmune Diseases complications, Immunoglobulin G blood, Neutropenia complications, Purpura, Thrombocytopenic, Idiopathic complications
- Abstract
IgG4-related disease (IgG4RD) is a multi-organ disorder characterized by an elevated serum IgG4 level and IgG4-positive plasma cell infiltration of the affected organs, accompanied by tissue fibrosis and sclerosis. Although it can affect any organ, to our knowledge, no cases involving concurrent autoimmune neutropenia and thrombocytopenia have been reported. A 62-year-old man visited our hospital and was diagnosed with IgG4RD accompanied by interstitial pneumonitis, lymphadenopathy, and interstitial nephritis. During his clinical course, he developed autoimmune neutropenia and idiopathic thrombocytopenic purpura. Our case, invoving multiple hematological abnormalities, might help deepen our understanding of the pathophysiology of IgG4RD.
- Published
- 2018
- Full Text
- View/download PDF
14. High pretransplant hepcidin levels are associated with poor overall survival and delayed platelet engraftment after allogeneic hematopoietic stem cell transplantation.
- Author
-
Sakamoto S, Kawabata H, Kanda J, Uchiyama T, Mizumoto C, Kitano T, Kondo T, Hishizawa M, Tomosugi N, and Takaori-Kondo A
- Subjects
- Adolescent, Adult, Aged, Female, Graft vs Host Disease epidemiology, Humans, Male, Middle Aged, Retrospective Studies, Survival Analysis, Transplantation, Homologous, Treatment Outcome, Young Adult, Hematologic Neoplasms blood, Hematologic Neoplasms therapy, Hematopoietic Stem Cell Transplantation adverse effects, Hepcidins blood
- Abstract
Iron overload is considered a risk factor for mortality in patients with hematopoietic malignancies. Hepcidin is a key regulator of systemic iron balance. We previously reported dynamic changes of serum hepcidin-25 levels in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this study, we retrospectively analyzed the association of pretransplant hepcidin-25 levels with overall survival (OS), engraftment, and other clinical outcomes of allo-HSCT in patients with hematologic malignancies. A total of 166 patients were divided into two groups depending on their pretransplant serum hepcidin-25 levels; their median age was 49.5 years, and the median follow-up time was 46.8 months. At 3 years, the patients in the high-hepcidin group had a significantly lower OS than those in the low-hepcidin group (49.2 vs. 69.0%, respectively; P = 0.006). Multivariate analysis revealed that pretransplant serum hepcidin-25 level, sex, and disease status were independently associated with OS. The incidence of platelet engraftment was significantly lower in the high-hepcidin group than in the low-hepcidin group, whereas no significant differences were observed in neutrophil and reticulocyte engraftments between these groups. Hence, pretransplant serum hepcidin levels can be a marker for predicting delayed platelet recovery after allo-HSCT., (© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
15. Sequential Use of Second-Generation Tyrosine Kinase Inhibitor Treatment and Intensive Chemotherapy Induced Long-Term Complete Molecular Response in Imatinib-Resistant CML Patient Presenting as a Myeloid Blast Crisis.
- Author
-
Tsuji M, Uchiyama T, Mizumoto C, Takeoka T, Tomo K, and Ohno T
- Abstract
Myeloid blast crisis of chronic myeloid leukemia (CML-MBC) is rarely seen at presentation and has a poor prognosis. There is no standard therapy for CML-MBC. It is often difficult to distinguish CML-MBC from acute myeloid leukemia expressing the Philadelphia chromosome (Ph+ AML). We present a case in which CML-MBC was seen at the initial presentation in a 75-year-old male. He was treated with conventional AML-directed chemotherapy followed by imatinib mesylate monotherapy, which failed to induce response. However, he achieved long-term complete molecular response after combination therapy involving dasatinib, a second-generation tyrosine kinase inhibitor, and conventional chemotherapy.
- Published
- 2017
- Full Text
- View/download PDF
16. H-Ferritin Is Preferentially Incorporated by Human Erythroid Cells through Transferrin Receptor 1 in a Threshold-Dependent Manner.
- Author
-
Sakamoto S, Kawabata H, Masuda T, Uchiyama T, Mizumoto C, Ohmori K, Koeffler HP, Kadowaki N, and Takaori-Kondo A
- Subjects
- Animals, Biological Transport, CHO Cells, Cell Line, Tumor, Cell Membrane metabolism, Cricetinae, Cricetulus, Ferritins metabolism, Humans, Antigens, CD metabolism, Apoferritins metabolism, Erythroid Cells metabolism, Receptors, Transferrin metabolism
- Abstract
Ferritin is an iron-storage protein composed of different ratios of 24 light (L) and heavy (H) subunits. The serum level of ferritin is a clinical marker of the body's iron level. Transferrin receptor (TFR)1 is the receptor not only for transferrin but also for H-ferritin, but how it binds two different ligands and the blood cell types that preferentially incorporate H-ferritin remain unknown. To address these questions, we investigated hematopoietic cell-specific ferritin uptake by flow cytometry. Alexa Fluor 488-labeled H-ferritin was preferentially incorporated by erythroid cells among various hematopoietic cell lines examined, and was almost exclusively incorporated by bone marrow erythroblasts among human primary hematopoietic cells of various lineages. H-ferritin uptake by erythroid cells was strongly inhibited by unlabeled H-ferritin but was only partially inhibited by a large excess of holo-transferrin. On the other hand, internalization of labeled holo-transferrin by these cells was not inhibited by H-ferritin. Chinese hamster ovary cells lacking functional endogenous TFR1 but expressing human TFR1 with a mutated RGD sequence, which is required for transferrin binding, efficiently incorporated H-ferritin, indicating that TFR1 has distinct binding sites for H-ferritin and holo-transferrin. H-ferritin uptake by these cells required a threshold level of cell surface TFR1 expression, whereas there was no threshold for holo-transferrin uptake. The requirement for a threshold level of TFR1 expression can explain why among primary human hematopoietic cells, only erythroblasts efficiently take up H-ferritin.
- Published
- 2015
- Full Text
- View/download PDF
17. Immune pancytopenia associated with a leukemic B-cell tumor carrying t(14;18)(q32;q21) translocation.
- Author
-
Mizumoto C, Ohno H, Katsurada T, Oguma S, and Yoshida Y
- Subjects
- Aged, Antibodies, Monoclonal, Murine-Derived therapeutic use, Antineoplastic Agents therapeutic use, Autoimmune Diseases diagnosis, Humans, Leukemia, B-Cell drug therapy, Male, Pancytopenia diagnosis, Rituximab, Treatment Outcome, Autoimmune Diseases etiology, Chromosomes, Human, Pair 14 genetics, Chromosomes, Human, Pair 18 genetics, Leukemia, B-Cell complications, Leukemia, B-Cell genetics, Pancytopenia etiology, Translocation, Genetic genetics
- Abstract
We report a 75-year-old man who was initially suggested to have acute leukemia. The hemoglobin level was 3.8 g/dL, white cell count was 7,700/µL with an absence of mature neutrophils and 69.0% leukemic cells, and platelet was 0.4 × 10(4)/µL. Coombs' antiglobulin test was positive. Leukemic cells were CD5(-), CD10(+), CD20(+), CD23(-), and IgG/λ(dim+). The bone marrow consisted of normal hematopoietic precursors, whereas fluorescence in situ hybridization detected the BCL2/IgH fusion gene. He was treated with rituximab-containing chemotherapy, resulting in the resolution of pancytopenia. The underlying disease was a leukemic B-cell tumor with t(14;18)(q32;q21), and the pancytopenia was mainly caused by autoimmune mechanisms.
- Published
- 2011
- Full Text
- View/download PDF
18. Clinical significance of serum hepcidin levels on early infectious complications in allogeneic hematopoietic stem cell transplantation.
- Author
-
Kanda J, Mizumoto C, Kawabata H, Ichinohe T, Tsuchida H, Tomosugi N, Matsuo K, Yamashita K, Kondo T, Ishikawa T, and Uchiyama T
- Subjects
- Adult, Bacterial Infections diagnosis, Bacterial Infections etiology, Biomarkers blood, Cytomegalovirus Infections diagnosis, Cytomegalovirus Infections etiology, Female, Hematologic Neoplasms therapy, Hepcidins, Humans, Iron Overload complications, Male, Middle Aged, Opportunistic Infections diagnosis, Risk, Transplantation, Homologous, Young Adult, Antimicrobial Cationic Peptides blood, Hematopoietic Stem Cell Transplantation adverse effects, Opportunistic Infections etiology, Predictive Value of Tests
- Abstract
The association of iron overload with complications of allogeneic hematopoietic stem cell transplantation (HSCT) has been suggested in previous studies. Because hepcidin plays a central role in the regulation of iron homeostasis, we analyzed the association between pretransplant serum hepcidin-25 levels and early infectious complications after allogeneic HSCT. We studied 55 consecutive adult patients with a median age of 47 years (range: 20-64 years) who underwent allogeneic HSCT for hematologic malignancies at our institution. Thirty-two patients had myelogenous malignancies; the remaining 23 had lymphogenous malignancies. The median pretransplant serum hepcidin level of patients in the study was 21.6 ng/mL (range: 1.4-371 ng/mL), which was comparable to that of healthy volunteers (median: 19.1 ng/mL [range: 2.3-37 ng/mL]; n = 17). When cumulative incidences of documented bacterial and cytomegalovirus (CMV) infections at day 100 were compared according to pretransplant hepcidin-25 levels, the incidence of bacterial, but not CMV, infection, was significantly higher in the high-hepcidin group (> or = 50 ng/mL; n = 17) than in the low-hepcidin group (<50 ng/mL; n = 38) (65% [95% confidence interval, 38%-82%] versus 11% [3%-23%]; P < .001). This finding was confirmed by multivariate Cox analysis adjusted for confounders, including pretransplant ferritin and C-reactive protein (CRP) levels. No fungal infection was documented in either group. These results suggest that the pretransplant serum hepcidin-25 level may be a useful marker for predicting the risk of early bacterial complications after allogeneic HSCT. Larger prospective studies are, however, warranted to confirm our findings.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.